For the millions of people who live with hyperpigmentation, the daily reality is rarely catastrophic and rarely simple. Dark patches from acne scarring, melasma triggered by pregnancy or hormonal contraception, and post-inflammatory marks that linger for months on deeper skin tones shape how people feel about their faces in a way that dermatology has historically underserved. Skinergy Beauty, a New York City skincare brand founded in 2017, has spent eight years building a small but decorated product line aimed squarely at that patient population [Skinergy Beauty website, retrieved 2026].
The company sells direct-to-consumer formulations for dark spots and skin discoloration, and its founder, Priscilla Jiminian, has been open about the personal origin story: products she remembered from the Dominican Republic, reformulated with United States-based chemists including Nicole Simpson, aimed at the kind of melanin-rich skin that often gets sidelined in mainstream skincare aisles [Epicenter NYC] [RETAILBOSS]. That focus, on a specific cosmetic concern in a specific demographic, is the wedge.
The bet
Skinergy's catalog centers on two products that have done most of the brand-building work: the Come Correct Serum, which won Hola Magazine's Best in Beauty in 2019, and the Dark Spot Correcting Cream, which took PopSugar's Best in LatinX award in 2021 [RETAILBOSS]. The company also cites a Self healthy beauty award in its press materials [RETAILBOSS]. Four awards across roughly four years is not a market-defining run, but for a pre-seed direct-to-consumer brand without disclosed institutional capital, editorial validation is the cheapest substitute for paid acquisition.
It is worth pausing on what the standard of care looks like today for hyperpigmentation, because it shapes how a brand like Skinergy gets evaluated by both customers and regulators. Dermatologists generally treat moderate to severe hyperpigmentation with prescription hydroquinone (typically 4 percent), tretinoin, azelaic acid, or compounded formulas, often paired with in-office procedures such as chemical peels or laser treatment. Over-the-counter alternatives lean on niacinamide, vitamin C, kojic acid, alpha arbutin, and tranexamic acid. None of these are regulated as drugs when sold cosmetically in the United States, which means the FDA evaluates them under cosmetic labeling rules rather than the efficacy standards applied to prescription depigmenting agents. A consumer brand competing in this category is competing on formulation quality, tolerability across skin tones, and trust, not on clinical claims it is permitted to make.
The niche could matter
The global market for products targeting hyperpigmentation has grown alongside broader interest in skincare for skin of color, a segment that legacy beauty conglomerates have publicly acknowledged underserving for decades. Brands that started with a clear point of view on melanin-rich skin, including Black-founded and Latina-founded labels, have moved from indie shelves into Sephora, Ulta, and Target over the past five years. Skinergy is positioned in that lineage. Its founder is Dominican American, its formulation story is rooted in Caribbean traditions, and its product naming and marketing speak directly to customers who have been told for years to simply wear more sunscreen and wait.
The upside case, if execution holds, is that Skinergy graduates from a DTC and small-retail footprint into a category-defining specialist brand for hyperpigmentation in deeper skin tones. That is a credible path. Several brands with similar origin stories have been acquired by strategics or have raised growth equity once they crossed eight-figure revenue. Skinergy has not disclosed revenue, and PitchBook lists it without confirmed funding rounds [PitchBook]. The brand is operating, by all public indications, as a founder-led independent.
The team and what is shipping
Jiminian has been the public face of the company since launch and has spoken in interviews about the eight-year build [Beauty News NYC Official] [Epicenter NYC]. The collaboration with formulator Nicole Simpson, named in coverage by Epicenter NYC, gives the product line a chemistry partner with a track record in independent beauty manufacturing. The company sells through its own site at skinergybeauty.com and has accumulated press coverage across beauty trade outlets and lifestyle media [Skinergy Beauty website, retrieved 2026].
| Recognition | Product | Year |
|---|---|---|
| Hola Magazine Best in Beauty | Come Correct Serum | 2019 |
| PopSugar Best in LatinX | Dark Spot Correcting Cream | 2021 |
| Self Healthy Beauty Award | Not specified | Not specified |
The honest counterfactual
What skeptics would point to is the structural difficulty of an independent skincare brand competing in a category where Unilever, L'Oreal, and Estee Lauder have meaningful product lines, alongside well-capitalized indies with celebrity backing. Customer acquisition costs in DTC beauty have risen sharply since 2021, and the path from awards-and-press to repeatable scaled revenue is the part that breaks most small brands. The bull answer, supported by the cited evidence, is that Skinergy is not trying to be a horizontal skincare brand. Its specialization in hyperpigmentation for melanin-rich skin is exactly the kind of narrow, identity-anchored positioning that has historically given indie founders a defensible wedge against larger players whose marketing speaks to everyone and therefore to no one [RETAILBOSS] [Epicenter NYC]. Whether that wedge converts into durable scale depends on retail distribution, repeat purchase behavior, and clinical-grade formulation work that the public record does not yet detail.
What to watch
The next twelve months will tell whether Skinergy stays in the founder-led indie tier or moves toward a first institutional round. Three things would signal momentum: a national retail partnership beyond DTC, a published clinical or consumer-perception study on the hyperpigmentation formulations (the kind of evidence that moves a cosmetic brand toward something a dermatologist would recommend), and any disclosed capital raise that would let the company invest in formulation depth and acquisition. None of those are promised, but each is a reasonable next step for a brand that has done the slow work of building a category reputation before chasing growth.
For the patient population at the center of this story, people living with melasma, post-inflammatory hyperpigmentation, and stubborn dark spots that conventional aisles have rarely addressed with care, the more independent specialists in the market, the better. Skinergy is one of them, and worth watching.
Pulse Raman, Health and Bio Correspondent, Startuply.